NMR studies with ME/CFS blood plasma identified decreases in glutamine and ornithine concentrations, suggesting abnormal amino acid metabolism and urea cycle dysregulation [108]
In addition, your metabolism will be enhanced, which may promote greater fitness as well as weight loss
Microdosing is not an FDA-approved regimen and has not been validated in clinical trials
Studies indicate that GLP-1 drugs reduce albuminuria and inflammatory markers in patients with diabetic nephropathy
Vertigo and dizziness may be caused by: Fluctuating blood sugar as your eating patterns shift Dehydration from reduced fluid intake, nausea, or vomiting Low blood pressure , particularly when standing up quickly Electrolyte imbalances due to dietary changes or fluid loss Rapid weight loss affecting your inner ear and balance Vestibular effects (your inner ear balance system) as a direct response to medication These symptoms often occur in the first few weeks after starting GLP-1 treatment or during dose increases
However, this advantage diminishes with combination therapy